

**PATENT APPLICATION**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:

Attorney Docket No: 101615-00026

WAJSZCZUK et al.

Confirmation No: 1997

Application No.: 10/611,653

Filed: July 2, 2003

For: METHODS FOR TREATING ESTROGEN-DEPENDENT DISORDERS

**INFORMATION DISCLOSURE STATEMENT**

Director of the U.S. PTO  
P.O. Box 1450  
Alexandria, VA 22313-1450

Date: November 21, 2003


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- ☒ 4. The references were cited by or submitted to the Office in parent application No. 09/770,911, filed January 26, 2001 which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these references are not attached. 37 CFR § 1.98(d).

Respectfully submitted,

  
Richard J. Berman  
Registration No. 44,634

Customer No. 004372  
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC  
1050 Connecticut Avenue, N.W., Suite 400  
Washington, D.C. 20036-5339  
Tel: (202) 857-6000; Fax: (202) 638-4810

RJB/ccd



FORM PTO-147

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

101615-00026

SERIAL NO.

10/611,653

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WAJSZCZUK et al.

FILING DATE

July 2, 2003

GROUP

Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	4560695	12/24/95	HIRSCH et al.			
	AB	4771043	9/13/88	FAUSTINI et al.			
	AC	4808616	2/28/89	BUZZETTI et al.			
	AD	4810423	3/7/89	BUZZETTI et al.			
	AE	4822528	4/18/89	COLOMBO et al.			
	AF	4824830	4/25/89	BUZZETTI et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AG	0165784	6/14/85	EPO					
	AH	0165777	6/14/85	EPO					
	AI	0574992	6/14/93	EPO					
	AJ	0025789	5/11/00	PCT					
	AK								
	AL								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Ricciardi, et al. "Tamoxifen-Induced Regression of Benign Breast Lesions", Obstetrics & Gynecology, Vol. 54, No. 1, pp 80-84 (1979)
	AN	Yen, "The Polycystic Ovary Syndrome", Clinical Endocrinology, 12, p. 177-208 (1990)
	AO	Jacquemier, et al., "Relationships between Steroid Receptor and Epithelial Cell Proliferation in Benign Fibrocystic Disease of the Breast", Cancer 49:2534-2536 (1982)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 3

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

101615-00026

SERIAL NO.

10/611,653

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WAJSZCZUK et al.

FILING DATE

July 2, 2003

GROUP

Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	4840943	6/20/89	BUZZETTI et al.			
	AB	4873233	10/10/89	VILLA et al.			
	AC	4904650	2/27/90	BUZZETTI et al.			
	AD	5457097	10/10/95	BUZZETTI et al.			
	AE	5502044	3/26/96	BUZZETTI et al.			
	AF	6025353	2/15/00	MASFERRER et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION		
							YES	NO	PART.
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Aiello et al., "Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins", Proc. Natl. acad. Sci. USA, Vol. 92, pp. 10457-10461 (1995)
	AN	Witte et al., "Monoclonal antibodies targeting the VEGF receptor-2 (Flk 1/KDR) as an anti-angiogenic therapeutic strategy", Cancer and Metastasis Reviews, 17, 99. 155-161 (1998)
	AO	Fairbrother et al., "Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site", Biochemistry, 37, 17754-17764 (1998).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

101615-00026

10/611,653

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT

WAJSZCZUK et al.

FILING DATE

July 2, 2003

GROUP

Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA	5126333	06/1992	MARTINI et al.			
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO PART.		
	AG								
	AH								
	AI								
	AJ								
	AK								
	AL								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	Bulun et al., "Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis", Endocrine-Related Cancer 6, 293-301 (1999)
	AN	Ryan et al., "Preclinical Safety Evaluation of rhuMAbVEGF, an Antiangiogenic Humanized Monoclonal Antibody", Toxicologic Pathology, Vol. 27, No. 1, pp 78-86 (1999)
	AO	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.